Recruiting

Testing a new imaging agent's safety in healthy people and cancer patients

Plain-English translation of NCT05799274 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a Phase 1 safety study of RAD301, a radioactive tracer designed to help doctors see tumors better during imaging scans. Researchers want to understand how safe RAD301 is and how your body uses and eliminates it. The study will include both healthy volunteers and people with pancreatic cancer or other solid tumors.

Before this new imaging agent can be used to help diagnose and monitor cancer, researchers need to confirm it is safe and understand how it moves through the body. This early-stage study will provide that crucial safety information.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you are able and willing to give informed consent to participate
you have a diagnosis of pancreatic cancer, lung cancer, esophageal cancer, cervical cancer, endometrial cancer, or ovarian cancer with evidence of disease on a recent CT or MRI scan (if you are a patient participant)
your blood counts and liver and kidney function tests are within acceptable ranges
you have a life expectancy of at least 12 weeks (if you are a patient participant)
your oxygen levels and heart rhythm on an ECG are normal

You likely don't qualify if…

you are pregnant or breastfeeding
you have had a severe allergic reaction to protein- or peptide-based medicines or diagnostic agents
you have significant liver or kidney disease that could affect how your body processes the medication
you are unable to lie still on an imaging table for the required scan periods
you have taken illicit drugs within the past week or plan to do so during the study

What participation looks like

You will visit the research clinic on one day to receive a single injection of the radioactive imaging agent. You will then undergo three imaging sessions (PET-CT scans) throughout the day—the first lasting about 2 hours, a second optional session of about 1.5 hours after a lunch break, and a final session later in the day. Before the injection and again 2 weeks later, you will have blood work and heart rhythm tests to check your safety. The entire study participation lasts about 2 weeks.

AI-generated summary from trial data · Aug 6, 2026 · Not medical advice

Trial locations(2 sites)

United States

United Theranostics, Princeton, New Jersey

Montefiore Medical Center, The Bronx, New York